Amyris Inc (fka AMRSQ)

[First Crown Research]

up 10% on no news except a delisting notice? This got market manipulation written all over it. Started a small short yesterday, but come Monday morning if it still acts like this, im shorting the hell out of it

[First Crown Research]

delisting notice ruh roh

[ClayTrader]

* * $AMRS Video Chart 04-09-2019 * *

Link to Video - click here to watch the technical chart video

[First Crown Research]

From the NT 10-K

"As previously reported in Part II, Item 9A, “Controls and Procedures” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, the Company has identified a material weakness in its internal control over financial reporting, which material weakness remains unremediated as of December 31, 2018. The Company is in the process of completing its evaluation of internal control over financial reporting and may have further deficiencies to report. In addition, the Company expects to continue to report that there is substantial doubt about its ability to continue as a going concern."

You guys have been warned by mgmt

[First Crown Research]

i just want to know where they're getting the cash for their bond payments. nothing more

[north40000]

Some innovative and useful aspects of genetic engineering seems to be working well for Amyris: fermentation of sugar cane husks, that once were mostly ignored as a raw material source.

The hybridized strain of pseudomonas bacteria in Diamond v. Chakrabarty, 447 U.S. 303(1980), was where/when I first became actively involved in litigation in genetic-engineering during the mid-1970s. GE did apply a strain to help clean up the Valdez oil spill. I doubt GE was able to monetize all its efforts to any great extent.
Perhaps GE will do better under new CEO Culp and the remains of its health sector. Our recent investments in GE have slightly negative value so far

Better monetization occurred by DNA and Roche with the cell culture of various recombinant molecules against the Bose patent, later canceled to be replaced by the DNA patent that was licensed and accrued healthy royalty sums for ~ two decades. I consulted with counsel representing DNA for two days in Scottsdale in proceedings leading to Roche/DNA obtaining the grant of the Cabllly patent. We never invested in either company(conflicts) except to the extent they carry weight in LABU.

We held/hold profitable, LT investments in IMCL(acquired by LLY); MEDX(acquired by BMY); AMLN(acquired by BMY/AZN); OCAT (acquired by Astellas) and GILD, CORT, VCEL, CPRX, ARYC, INSM, JNJ, SGEN, and AMRN, among others.

I’ll leave the collection of the loose change that you mention to you. We invested in Amyris for substantial value creation; we bought further shares today.

Both of us recognize that ST and LT losses do exist; we have our share of those too.

[First Crown Research]

i mean it's not like the problem im raising happened today lol it's been happening for years (notice how it used to trade in the 40's and now it's at 3?) hahah ... i assume you're long. good luck picking up dimes in front of bulldozers

[north40000]

IR couldn’t give you an answer, There could be many reasons:

1) Each of AMRS, AAPL and AMZN are considered “disruptive” of numerous industry sectors at the moment. Perhaps AMRS is in negotiations that are not yet complete? Similarly

2) JNJ once disrupted the artificial sweetener industry with its chlorinated sugar molecule? AMRS now has a new, different, disruptive artificial sweetener.

Whatever, the market did not seem particularly concerned today about any problem you sought to raise.

[First Crown Research]

according to finra its about 74m due on monday

[north40000]

How much of of a payment do you think is due? When do you think that amount is due?

[First Crown Research]

i have. they couldnt give me an answer

[north40000]

Why not call IR and ask them your question?

http://investors.amyris.com/news-releases/news-release-details/amyris-reports-fourth-quarter-and-fiscal-year-2018-financial

[First Crown Research]

i just want to know how they're going to make their bond payment monday. that is all.

[north40000]

AMRS: looks like you are concentrating on the wrong sector that AMRS is engaged in, judging from gainers today-- PRs?

Laredo Petroleum, Crescent Point Energy, AMRS are currently + 7-12%.
.

[ClayTrader]

* * $AMRS Video Chart 04-05-2019 * *

Link to Video - click here to watch the technical chart video

[Golden Cross]

$AMRS Daily Chart: RSI ready to turn bullish

[ClayTrader]

* * $AMRS Video Chart 04-04-2019 * *

Link to Video - click here to watch the technical chart video

[beambe]

good Volume

[Bhagina]

Back to $10. Huge deal news coming.

[ClayTrader]

* * $AMRS Video Chart 04-03-2019 * *

Link to Video - click here to watch the technical chart video

[First Crown Research]

gotchya. thank you. so it was registered 2/22/19 .

[treppy]

Delaware

[First Crown Research]

what state is LAVVAN even registered in?

and im not alleging it's a fraud. that's a whole different legal standard. But do i think the equity is worth a 0? absolutely

[SubstitutedPinions]

Sorry, bro. Like, let me break it down for ya. They wanna be secret, so, like, um...don’t leave a trail. But the, like other side of the coin is like they’ve already done too much to not be real...’cause if it was some big frickin’ fraud, they just incriminated themselves.

Did that work? Make sense?

[First Crown Research]

what are you even talking about lolololol sounds like you might be using too many cannabinoid products

[SubstitutedPinions]

If the idea is to remain anonymous (and it is) then it’s hard not to leave a trail in building their web presence out more. It’s also, by the way, easy to prove deception with what they’ve already done if you say that’s their aim (it is not). Conclusion is it’s legit.

[beambe]

good Volume

[First Crown Research]

alright folks, usually i dont get into the battle this early but this co. is GARBAGE .... i mean the co. they've partnered with 'LAVVAN' ... .their website was registered TWO WEEKS AGO. DESPERATE BS .... they will not be able to make their maturities. You cant wait until you have 0 cash to file for bk and the cushion they have is no where close to what's needed. shorting as much as i can find

[Golden Cross]

RSI popped up from being oversold today! Looking good here...

[ClayTrader]

* * $AMRS Video Chart 03-27-2019 * *

Link to Video - click here to watch the technical chart video

[north40000]

Today is much better for us; and you too?

[whytestocks]

News: $AMRS Amyris to Present April 15 at Paradigm Capital Biosynthesis Conference - Exploring the Most Disruptive Technology in the Cannabis Industry

EMERYVILLE, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that management will be presenting at th...

Read the whole news https://marketwirenews.com/news-releases/amyris-to-present-april-15-at-paradigm-capital-biosynthesis-conference-exploring-the-most-disruptive-technology-in-the-cannabis-industry-7899086.html

[LodieJ]

$AMRS played some real dirty pool with the way they threw out certain news articles. They ought to be sued over it. Shady shady. However....I expect the GOOD NEWS will start now at some point....

[ShadowSpy69]

glad I was migrating to ATRS since last fall. Still stings a tad but oh well. Who the hell knows with this pos now... cry wolf too many times and some day someone will call the bluff.

SMH

[mrinvestor08]

Glad I only put $5k in this...but I think we will rise up again. They have lots more in the tank.

Melo reminds me of eves lol

[ClayTrader]

* * $AMRS Video Chart 03-22-2019 * *

Link to Video - click here to watch the technical chart video

[cspratt15139]

He brings them short sellers for sure

[treppy]

Go home clay nobody likes you. Look at the discussion here it’s crickets. You scared everyone away lol. There is barn Fire and you are go to going to about stupid stairs. Use those stairs to get out of here

[ClayTrader]

* * $AMRS Video Chart 03-21-2019 * *

Link to Video - click here to watch the technical chart video

[BottomBounce]

$AMRS Amyris 4Q Loss/Shr $1.03 >AMRS

[ClayTrader]

* * $AMRS Video Chart 02-15-2019 * *

Link to Video - click here to watch the technical chart video

[ShadowSpy69]

LoL :p

[simmons420]

LoL ?? riiight, long here

[ShadowSpy69]

blah blah blah go away

[ClayTrader]

* * $AMRS Video Chart 02-12-2019 * *

Link to Video - click here to watch the technical chart video

[MDizzle]

Amyris Is Selected by NIH Grant Recipient, IDRI, to Engineer Molecules for Vaccine Adjuvant Applications



Amyris, Inc. (Nasdaq:AMRS), and IDRI (Infectious Disease Research Institute), are pleased to announce IDRI’s receipt of a $4.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases (part of the U.S. National Institutes of Health) to discover sustainable alternatives to shark squalene to use as vaccine adjuvants (grant number: R01AI135673). Funding is provided by a special bioengineering research grant aimed at bringing engineering expertise to focus on a biomedical problem and ultimately develop a new solution.
Adjuvants are added to vaccines to enhance their effectiveness; the aim of the new project is to discover and evaluate novel, sustainable squalene-like compounds produced by bio- or chemical engineering for vaccine adjuvant applications.

IDRI has selected Amyris and the University of Nottingham, (UK) as partners because of their record of success in engineering pure molecules from sustainable sources at low cost. Instead of sourcing squalene from sharks, Amyris uses patented biotechnology to create squalene-like compounds using sugarcane syrup as the fermentation feedstock. Amyris has developed specific expertise as a clean manufacturer of sustainably sourced squalane.

“While one of our goals is to find a replacement for the pharmaceutical squalene derived from sharks, another key driver of this project is to understand how squalene formulations actually work as adjuvants,” said Christopher Fox, PhD, Vice President of Formulations at IDRI and principal investigator for the project. “By generating compounds with various structural alterations, we can study the structure-function relationship of squalene-like molecules and shine a light on their mechanisms of action.”

Fox added that key attributes of adjuvants in vaccines are the ability to improve an immune response and minimize the dose of vaccine necessary to confer immunity, which is particularly important where there is a disease outbreak that results in a vaccine shortage. “Development of this technology could enable formulations that effectively increase the number of vaccine doses available in the event of an influenza pandemic for example,” Fox said.

“We’re pleased to assist IDRI and to work with the University of Nottingham in this endeavor,” Amyris President, Research & Development Joel Cherry, Ph.D. said. “Today, we’re producing enormous amounts of squalane for customers around the world. This is a sustainably sourced version of squalane, with high purity and performance, and we’re looking forward to lending our assistance to apply what we know to benefit more people.”

[treppy]

[ClayTrader]

* * $AMRS Video Chart 02-11-2019 * *

Link to Video - click here to watch the technical chart video

[MDizzle]

Amyris Appoints Industry Veteran as President, Sweeteners and Ingredients, to Deliver Accelerated Growth



EMERYVILLE, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced the appointment of Oreste Fieschi as President of Sweeteners & Ingredients, to lead the commercial growth of its sweetener business and the implementation of its strategy to build capability across the entire ingredients portfolio.

Oreste has a successful track record in commercial leadership roles in the food and beverage and natural ingredients sectors, along with deep expertise in global markets. This new position is driven by growth across Amyris's businesses and within the expanding market for the company's new, sugarcane-derived zero calorie sweetener.

Most recently, he led global sales and marketing as the Chief Commercial Officer for Naturex, a leader in natural ingredients recently bought by Givaudan. He has over 20 years' experience in senior commercial roles in diverse markets including chemicals, personal care, and food & beverage, including six years leading the sales growth strategy for Tate & Lyle Latin America. Prior to that, he held key commercial and business development roles with such companies as IFF, a leading developer and manufacturer of flavors and fragrances. Oreste holds a Master's degree in Business Administration from the Business School São Paulo, BSP (in partnership with Toronto University), and several other education certifications in finance and accounting, marketing, and chemical engineering.

"We welcome Oreste to Amyris at an inflection point when our businesses are experiencing solid, recurring revenue growth," said John Melo, Amyris President & CEO. "His proven experience as a successful leader in the markets we are growing, gives us a significant advantage toward maximizing the real opportunities ahead of us for revenue growth through key partnerships for our No Compromise(TM) ingredients."

Based in São Paulo and fluent in English, Portuguese and Spanish, Oreste will leverage his deep expertise globally to execute on Amyris's accelerated demand for the sweetener business.

[treppy]

Not being an Internet tough guy. You come around on big volume and your videos are basic.